| Adalimumab + methotrexate (N = 261) | Adalimumab monotherapy (N = 261) | Methotrexate monotherapy (N = 246) | |
| Demographic characteristics | |||
| Age, years | 52.2 (13.8) | 51.9 (13.7) | 51.9 (13.3) |
| Female, no (%) | 187 (71.6) | 205 (78.5) | 181 (73.6) |
| Clinical characteristics | |||
| Disease duration, years | 0.7 (0.8) | 0.7 (0.8) | 0.8 (0.9) |
| Previously taken DMARD, no (%) | 84 (32.2) | 87 (33.3) | 78 (31.7) |
| Previously taken corticosteroids, no (%) | 92 (35.2) | 94 (36.0) | 85 (34.6) |
| Tender joint count, 0–66 | 31.1 (14.1) | 31.7 (13.5) | 32.2 (14.3) |
| Swollen joint count, 0–66 | 21.2 (11.1) | 21.7 (10.2) | 21.6 (11.3) |
| C-reactive protein, mg/l | 39.5 (42.4) | 40.7 (38.6) | 40.6 (41.2) |
| HAQ, 0–3 | 1.5 (0.6) | 1.6 (0.6)† | 1.5 (0.7) |
| DAS28 | 6.3 (0.9) | 6.4 (0.9) | 6.3 (0.9) |
| Image analysis | |||
| Modified TSS | |||
| Mean | 18.1 (20.3) | 18.4 (18.2) | 21.5 (21.8) |
| Median (25–75th percentile) | 12.8 (6.0–24.0) | 13.5 (5.1–25.5) | 15.5 (7.5–28.5) |
| DXR–MCI | 0.45 (0.09) | 0.45 (0.09) | 0.46 (0.08) |
| DXR–BMD, g/cm2 | 0.57 (0.08) | 0.57 (0.08) | 0.58 (0.08) |
*Except where indicated results are given in mean (standard deviation) for continuous variables and numbers and percentages for categorical variables. †Significantly higher values in the adalimumab group compared with both the methotrexate and the combination group. BMD, bone mineral density; DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drugs; DXR, digital x ray radiogrammetry; HAQ, health assessment questionnaire; MCI, metacarpal cortical index; RA, rheumatoid arthritis; TSS, total Sharp score.